Cargando…
Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3
PR-104 is a phosphate ester pre-prodrug that is converted in vivo to its cognate alcohol, PR-104A, a latent alkylator which forms potent cytotoxins upon bioreduction. Hypoxia selectivity results from one-electron nitro reduction of PR-104A, in which cytochrome P450 oxidoreductase (POR) plays an impo...
Autores principales: | Abbattista, Maria R., Ashoorzadeh, Amir, Guise, Christopher P., Mowday, Alexandra M., Mittra, Rituparna, Silva, Shevan, Hicks, Kevin O., Bull, Matthew R., Jackson-Patel, Victoria, Lin, Xiaojing, Prosser, Gareth A., Lambie, Neil K., Dachs, Gabi U., Ackerley, David F., Smaill, Jeff B., Patterson, Adam V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707548/ https://www.ncbi.nlm.nih.gov/pubmed/34959631 http://dx.doi.org/10.3390/ph14121231 |
Ejemplares similares
-
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
por: Guise, Christopher P., et al.
Publicado: (2014) -
Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications
por: Ashoorzadeh, Amir, et al.
Publicado: (2022) -
The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach
por: Ball, Patrick, et al.
Publicado: (2023) -
The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104
por: Foehrenbacher, Annika, et al.
Publicado: (2013) -
A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients
por: McKeage, Mark J, et al.
Publicado: (2011)